{"schema_version":"secwatch.filing_event.v1","accession":"0001737287-22-000081","form_type":"8-K","ticker":"ALLO","cik":"0001737287","company_name":"Allogene Therapeutics, Inc.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.928076+00:00","generated_at":"2026-06-22T14:47:11.586747+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Allogene reports Q3 net loss of $83.1M; initiates first allogeneic CAR T Phase 2 trial","bullets":["Net loss $83.1M ($0.58/share); R&D expenses $63.6M; G&A $18.9M.","Cash & investments $637M at Sep 30; 2022 cash burn guidance <$250M.","Initiated ALPHA2 Phase 2 trial of ALLO-501A in relapsed/refractory large B-cell lymphoma.","R&D Showcase on Nov 29, 2022 to feature updated CD19 and BCMA data.","FY 2022 GAAP operating expenses slightly below prior $360M-$390M guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0001737287-22-000081","json":"https://secwatch.observer/filing/0001737287-22-000081.json","markdown":"https://secwatch.observer/filing/0001737287-22-000081.md","text":"https://secwatch.observer/filing/0001737287-22-000081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737287/000173728722000081/0001737287-22-000081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737287/000173728722000081/allo-20221102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T14:47:11.586747+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"55e31fbcaa9bf2a4809f57501c025c8ff75db711","claim":"Allogene Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income $83.1 million, EPS $0.58 per share.","evidence_excerpt":"Net loss for the third quarter of 2022 was $83.1 million, or $0.58 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728722000081/0001737287-22-000081-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"$83.1 million"},{"label":"EPS","value":"$0.58 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}